[1] Cai W, Chen X. Multimodality imaging of vascular endothelial growth factor and vascular endothelial growth factor receptor expression[J]. Front Biosci, 2007, 12:4267-4279.  doi: 10.2741/2386
[2] Stacy MR, Maxfield MW, Sinusas AJ. Targeted molecular imaging of angiogenesis in PET and SPECT:a review[J]. Yale J Biol Med, 2012, 85(1):75-86.
[3] Ellis LM, Liu W, Ahmad SA, et al. Overview of angiogenesis:Biologic implications for antiangiogenic therapy[J]. Semin Oncol, 2001, 28(5):94-104.
[4] Lijowski M, Caruthers S, Hu G, et al. High sensitivity:high-resolution SPECT-CT/MR molecular imaging of angiogenesis in the Vx2 model[J]. Invest radiology, 2009, 44(1):15-22.
[5] Eliceiri BP, Cheresh DA. Role of alpha v integrins during angiogenesis[J]. Cancer J, 2000, 6 Supple3:S245-249.
[6] Hynes RO, Bader BL, Hodivala-Dilke K. Integrins in vascular development[J]. Braz J Med Biol Res, 1999, 32(5):501-510.  doi: 10.1590/S0100-879X1999000500002
[7] Tischer E, Mitchell R, Hartman T, et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing[J]. J Biol Chem, 1991, 266(18):11947-11954.
[8] Quinn TP, Peters KG, De Vries C, et al. Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium[J]. Proc Natl Acad Sci USA, 1993, 90(16):7533-7537.  doi: 10.1073/pnas.90.16.7533
[9] Millauer B, Wizigmann-Voos S, Schnürch H, et al. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis[J]. Cell, 1993, 72(6):835-846.  doi: 10.1016/0092-8674(93)90573-9
[10] Yoshimoto M, Kinuya S, Kawashima A, et al. Radioiodinated VEGF to image tumor angiogenesis in a LS180 tumor xenograft model[J]. Nucl Med Biol, 2006, 33(8):963-969.  doi: 10.1016/j.nucmedbio.2006.08.006
[11] Blankenberg FG, Mandl S, Cao YA, et al. Tumor imaging using a standardized radiolabeled adapter protein docked to vascular endothelial growth factor[J]. J Nucl Med, 2004, 45(8):1373-1380.
[12] Blankenberg FG, Backer MV, Levashova Z, et al. In vivo tumor angiogenesis imaging with site-specific labeled Tc-99m-HYNIC-VEGF[J]. Eur J Nucl Med Mol Imaging, 2006, 33(7):841-848.  doi: 10.1007/s00259-006-0099-1
[13] Chan C, Sandhu J, Guha A, et al. A human transferrin-vascular endothelial growth factor(hnTf-VEGF)fusion protein containing an integrated binding site for(111) In for imaging tumor angiogenesis[J]. J Nucl Med, 2005, 46(10):1745-1752.
[14] Qin ZX, Li QW, Liu GY, et al. Imaging targeted at tumor with(188) Re-labeled VEGF(189) exon 6-encoded peptide and effects of the transfecting truncated KDR gene in tumor-bearing nude mice[J]. Nucl Med Biol, 2009, 36(5):535-543.
[15] Nagengast WB, de Vries EG, Hospers GA, et al. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft[J]. J Nucl Med, 2007, 48(8):1313-1319.  doi: 10.2967/jnumed.107.041301
[16] Nagengast WB, Hooge MN, van Straten EM, et al. VEGF-SPECT with In-111-bevacizumab in stage Ⅲ/IV melanoma patients[J]. Eur J Cancer, 2011, 47(10):1595-1602.  doi: 10.1016/j.ejca.2011.02.009
[17] Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease[J]. Nat Med, 1995, 1(1):27-31.  doi: 10.1038/nm0195-27
[18]

Haubner R, Maschauer S, Einsiedel J, et al. H-CRRETAWAC-OH, a Lead structure for the development of radiotracer targeting integrin α5β1?[J/OL]. Biomed Res Int, 2014: 243185[2014-10-20].http://www. hindawi. com/journals/bmri/2014/243185/.
[19] Haubner R, Wester HJ, Burkhart F, et al. Glycosylated RGD-containing peptides:tracer for tumor targeting and angiogenesis imaging with improved biokinetics[J]. J Nucl Med, 2001, 42(2):326-336.
[20] van Hagen PM, Breeman WA, Bernard HF, et al. Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumour imaging and radionuclide therapy[J]. Int J Cancer, 2000, 90(4):186-198.
[21] Sivolapenko GB, Skarlos D, Pectasides D, Stathopoulou E, et al. Imaging of metastatic melanoma utilising a technetium-99m labelled RGD-containing synthetic peptide[J]. Eur J Nucl Med, 1998, 25(10):1383-1389.  doi: 10.1007/s002590050312
[22] Fu T, Qu W, Qiu F, et al. 99Tcm-3P-RGD2 micro-single-photon emission computed tomography/computed tomography provides a rational basis for integrin αvβ3-targeted therapy[J]. Cancer Biother Radiopharm, 2014, 29(9):351-358.  doi: 10.1089/cbr.2014.1622
[23] Bach-Gansmo T, Bogsrud TV, Skretting A. Integrin scintimam-mography using a dedicated breast imaging, solid-state gamma-camera and(99m) Tc-labelled NC100692[J]. Clin Physiol Funct Imaging, 2008, 28(4):235-239.  doi: 10.1111/j.1475-097X.2008.00801.x
[24] Axelsson R, Bach-Gansmo T, Castell-Conesa J, et al. An open-label, multicenter, phase 2a study to assess the feasibility of imaging metastases in late-stage cancer patients with the alpha v beta 3-selective angiogenesis imaging agent 99mTc-NC100692[J]. Acta radiol, 2010, 51(1):40-46.
[25] Shi JY, Kim YS, Chakraborty S, et al. Impact of bifunctional chelators on biological properties of In-111-labeled cyclic peptide RGD dimers[J]. Amino Acids, 2011, 41(5):1059-1070.  doi: 10.1007/s00726-009-0439-0
[26] Terry SY, Abiraj K, Lok J, et al. Can 111In-RGD2 monitor response to therapy in head and neck tumor xenografts[J]. J Nucl Med, 2014, 55(11):1849-1855.  doi: 10.2967/jnumed.114.144394
[27] Demartis S, Tarli L, Borsi L, et al, Selective targeting of tumour neovasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectin[J]. Eur J Nucl Med, 2001, 28(4):534-539.
[28] Berndorff D, Borkowski S, Moosmayer D, et al. Imaging of tumor angiogenesis using 99mTc-labeled human recombinant anti-ED-B fibronectin antibody fragments[J]. J Nucl Med, 2006, 47(10):1707-1716.
[29] Chang SS, O'keefe DS, Bacich DJ, et al. Prostate-specific membrane antigen is produced in tumor-associated neovasculature[J]. Clin Cancer Res, 1999, 5(10):2674-2681.
[30] Morris MJ, Pandit-Taskar N, Divgi CR, et al. Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors[J]. Clinical Cancer Research, 2007, 13(9):2707-2713.  doi: 10.1158/1078-0432.CCR-06-2935
[31] Vallabhajosula S, Nikolopoulou A, Babich JW, et al. 99Tcm-labeled small-molecule inhibitors of prostate-specific membrane antigen:pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer[J]. J Nucl Med, 2014, 55(11):1791-1798.  doi: 10.2967/jnumed.114.140426